The primary purpose of this study is to assess the ability of scopolamine to improve the
antidepressant effects of ECT and to determine whether scopolamine will shorten the time to
response and remission for patients receiving ECT.
The hypothesis are:
1. Patients receiving ECT plus scopolamine will have greater improvement in depression
symptoms than those receiving ECT plus placebo.
2. Patients receiving scopolamine in addition to ECT will require fewer ECT treatments to
obtain response/remission compared to the group receiving ECT plus placebo.
3. Time to response and to remission in the scopolamine group will be significantly shorter
compared to ECT alone.